New, popular injectable weight loss drugs — GLP-1 drugs — are highly effective at reducing obesity and, probably, the health risks posed by obesity. Yet the drugs are so expensive that insurers are often choosing between two bad options: restricting access or raising consumer costs.

,A weight-loss drug more effective than Ozempic and Wegovy has recently been approved in Australia. The drug, tirzepatide, is sold under the brand name Mounjaro and affects feelings of hunger and fullness, as well as changing how the body processes food. (In other countries, tirzepatide is also sold under the brand name Zepbound.)